Phase I/II study of 131I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma |
| |
Authors: | S G DuBois S Allen M Bent J F Hilton F Hollinger R Hawkins J Courtier Y P Mosse K K Matthay |
| |
Institution: | 1.Department of Pediatrics, UCSF School of Medicine, UCSF Benioff Children''s Hospital, San Francisco, CA 94143, USA;2.Department of Epidemiology and Biostatistics, UCSF School of Medicine, San Francisco, CA 94143, USA;3.Department of Radiology, UCSF School of Medicine, San Francisco, CA 94143, USA;4.Department of Pediatrics, University of Pennsylvania School of Medicine and Children''s Hospital of Philadelphia, Philadelphia, PA 19104, USA |
| |
Abstract: | Background: 131I-metaiodobenzylguanidine (MIBG) is an active radiopharmaceutical in neuroblastoma. A previous study demonstrated that MIBG could be combined with vincristine and prolonged irinotecan, although 25% of first courses had grade 3 diarrhoea. The current phase I/II study evaluated MIBG with vincristine and 5 days of higher-dose irinotecan.Methods: Patients 1–30 years old with advanced neuroblastoma were eligible. Patients received cefixime on days −1 to +6, irinotecan (50 mg m−2 per dose IV) on days 0–4, vincristine (2 mg m−2) on day 0, MIBG (555 or 666 MBq kg−1) on day 1, and peripheral blood stem cells on day 13. UGT1A1 genotyping was performed in consenting patients.Results: Thirty-two patients (12 phase I ; 20 phase II) received 42 courses. No dose-limiting toxicities were seen during dose escalation and the recommended administered activity was 666 MBq kg−1. Myelosuppression and diarrhoea were the most common toxicities, with grade 3 diarrhoea in 6% of first courses. Patients homozygous for UGT1A1*28 had more grade 4 thrombocytopenia (80% vs 37% P=0.14). Responses (five complete and four partial) occurred in 9 out of 32 (28%) patients.Conclusions: MIBG (666 MBq kg−1) with vincristine and this irinotecan schedule is tolerable and active, with less severe diarrhoea compared with a regimen using more protracted irinotecan. |
| |
Keywords: | 131I-MIBG irinotecan vincristine neuroblastoma UGT1A1 |
|
|